Selected References:

  • Artama M, et al. 2013. Drug and Pregnancy Group: Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 36(5):359-369.
  • Bech BH, et al. 2014. Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study. BMJ 349:g5159.
  • Christensen et al. 2013. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309(16):1696-703.
  • Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals 6(10):1221-1286.
  • Kilic D, et al. 2014. Birth outcomes after prenatal exposure to antiepileptic drugs–a population-based study. Epilepsia 55(11):1714-1721.
  • Oberlander TF, et al. 2004. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65(2):230-237.
  • Vajda FJE, et al. 2014. The teratogenicity of the newer antiepileptic drugs – an update. Acta Neurol Scand 130(4):234-238.
  • Veiby G, et al. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261(3):579-588.
  • Veiby G, et al. 2015. Epilepsy and recommendations for breastfeeding. Seizure 28:57-65.
  • Veroniki, AA, et al. 2017. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open 7(7):e017248.
  • Weinstock L, et al. 2001. Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series. Psychother Psychosom 70(3):158-162.